Company Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.
The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
| Country | United States |
| Founded | 1979 |
| IPO Date | Feb 12, 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 122 |
| CEO | Dr. Jacqueline E. Shea Ph.D. |
Contact Details
Address: 6769 Mesa Ridge Rd. San Diego, California 92121 United States | |
| Phone | (858) 410-3134 |
| Website | inovio.com |
Stock Details
| Ticker Symbol | INO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001055726 |
| CUSIP Number | 45773H201 |
| ISIN Number | US45773H4092 |
| Employer ID | 33-0969592 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jacqueline E. Shea Ph.D. | Chief Executive Officer, President and Director |
| Peter D. Kies | Chief Financial Officer |
| Dr. Laurent M. Humeau Ph.D. | Chief Scientific Officer |
| Thomas Hong | Manager of Investor Relations |
| Robert L. Crotty J.D. | General Counsel and Chief Compliance Officer |
| E. J. Brandreth MBA | Senior Vice President of Quality Assurance |
| Dr. Jeffrey Skolnik | Senior Vice President of Clinical Development |
| Robert J. Juba Jr. | Senior Vice President of Biological Manufacturing and Clinical Supply Management |
| Stephen Kemmerrer M.B.A., P.E. | Senior Vice President of Engineering Development |
| Shawn D. Bridy M.A., M.B.A. | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K | Current Report |
| Apr 17, 2024 | 424B5 | Filing |
| Apr 15, 2024 | ARS | Filing |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 6, 2024 | 10-K | Annual Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | EFFECT | Notice of Effectiveness |
| Jan 26, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jan 25, 2024 | 8-K | Current Report |
| Jan 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |